1. Diamandis EP. Tumor markers: past, present, and future. In Tumor Markers: Physiology, Pathobiology, Technology, and Clinical Applications, EP Diamandis, H Fritsche, Jr, H Lilja, D Chan, M Schwartz (eds). Washington, DC, American Association for Clinical Chemistry (AACC) Press, 2002, pp 3–8.
2. Hayes DF, Bast RC, Desch CE, Fritsche H, Jr, Kemeny NE, Jessup JM, Locker GY, Macdonald JS, Mennel RG, Norton L, Ravdin P, Taube S, Winn RJ. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456–1466.
3. Meunier, F. European Organisation for Research and Treatment of Cancer. Brussels, EORTC, 2006 (http://www.eortc.be).
4. Schmitt M, Harbeck N, Daidone MG, Brunner N, Duffy MJ, Foekens JA, Sweep FC. Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: tasks of the Receptor and Biomarker Group of the European Organization for Research and Treatment of Cancer. Int J Oncol 2004;5:1397–1406.
5. Schrohl AS, Holten-Andersen M, Sweep F, Schmitt M, Harbeck N, Foekens J, Brunner N. European Organisation for Research and Treatment of Cancer (EORTC) Receptor and Biomarker Group. Tumor markers: from laboratory to clinical utility. Mol Cell Proteomics 2003;6:378–87.